Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
Rhea-AI Summary
Decoy Therapeutics (Nasdaq: DCOY) will present at the Corporate Connect Webinar Series hosted by Webull Financial on Tuesday, February 10, 2026 at 1:20 PM EST.
CEO Rick Pierce will give a brief corporate overview and highlight the company's new class of antiviral peptide conjugate therapeutics that target multiple viral pathogens.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, DCOY declined 1.59%, reflecting a mild negative market reaction. Argus tracked a peak move of +10.0% during that session. Argus tracked a trough of -15.5% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $81K from the company's valuation, bringing the market cap to $5M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 04 | Investor webcast | Positive | -7.6% | Virtual segment explaining Global Access Commitment Agreement with Gates Foundation. |
| Jan 13 | Strategic funding news | Positive | +53.4% | Global Access Commitment Agreement to fund scalable peptide-conjugate platform. |
Recent Gates Foundation-related news produced mixed reactions: one large gain and one decline on generally positive developments.
Over the past month, Decoy Therapeutics has focused on its Gates Foundation-backed initiatives. On Jan 13, 2026, a Global Access Commitment Agreement and plans for a scalable peptide-conjugate platform coincided with a 53.37% move. A follow-up virtual investor segment on Feb 4, 2026 saw a -7.62% reaction. Today’s webinar participation announcement continues the investor-outreach theme against this mixed trading backdrop.
Market Pulse Summary
This announcement highlights Decoy’s participation in a virtual webinar, offering a corporate overview and discussion of its peptide-conjugate antiviral approach. Recent history includes a Gates Foundation-backed Global Access Commitment Agreement on Jan 13, 2026 and a follow-on investor segment on Feb 4, 2026, with mixed price reactions. Investors may watch for further updates on development timelines, regulatory milestones, and any concrete data readouts that build on these outreach efforts.
Key Terms
peptide conjugate therapeutics medical
antiviral therapeutics medical
AI-generated analysis. Not financial advice.
– Live video webcast on Tuesday, February 10th at 1:20 PM EST
As part of the presentation, Rick Pierce, Chief Executive Officer of Decoy Therapeutics, will provide a brief corporate overview, highlighting its new class of antiviral therapeutics that can target multiple viral pathogens with a single drug.
Details of the presentation are as follows:
Date and Time: Tuesday, February 10, 2026 at 1:20 PM EST
Presenter: Rick Pierce, Chief Executive Officer of Decoy Therapeutics
Registration Link: Here
About Webull Financial
Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology. With low-cost trading on a wide range of assets, advanced charting tools, and real-time market data, Webull is revolutionizing the way individuals approach investing. The user-centric approach and commitment to staying at the forefront of industry trends underscore the mission to provide a seamless and rewarding experience for traders of all levels. Through the Webull Group, Webull Financial and its affiliates combine to serve tens of millions of users from over 180 countries worldwide. Securities and futures trading is offered to customers by Webull Financial LLC ("Webull Financial"), a broker-dealer registered with the Securities and Exchange Commission (SEC) and a futures commission merchant registered with the Commodity Futures Trading Commission (CFTC). Webull Financial is a member of the Financial Industry Authority (FINRA), the National Futures Association (NFA), and the Securities Investor Protection Corporation (SIPC). All investing is subject to risk, including the possible loss of principal. For more information about Webull, visit www.webull.com.
About Decoy Therapeutics, Inc.
Decoy Therapeutics is a preclinical-stage biotechnology company that is leveraging ML and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The company's initial pipeline is focused on respiratory viruses and GI cancers. Decoy has attracted financing from institutional investors as well as significant non-dilutive capital from the Massachusetts Life Sciences Seed Fund, the Google AI startup program and the NVIDIA Inception program among other sources. The company has also received QuickFire Challenge award funding provided by the Biomedical Advanced Research and Development Authority (BARDA) through BLUE KNIGHT™, a collaboration between Johnson & Johnson Innovation – JLABS and BARDA within the Administration for Strategic Preparedness and Response.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Decoy, including expected achievement of milestones for its lead asset and future prospects of Decoy. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Decoy, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "can," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risk that the Company will not obtain sufficient financing to execute on their business plans and risks related to Decoy's products and development plans, including unanticipated issues with any IND application process and the potential of the IMP3ACT™ platform. Readers are urged to carefully review and consider the various disclosures made by the Company in its reports filed with the SEC, including its Current Report on Form 8-K filed on August 22, 2025, its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, Decoy's actual results may vary materially from those expected or projected.
View original content to download multimedia:https://www.prnewswire.com/news-releases/decoy-therapeutics-to-participate-in-the-corporate-connect-webinar-series-virtual-conference-hosted-by-webull-financial-302679604.html
SOURCE Decoy Therapeutics, Inc
FAQ
When will Decoy Therapeutics (DCOY) present at the Webull Corporate Connect Webinar Series?
Who will represent Decoy Therapeutics (DCOY) at the February 10, 2026 webinar?
What topics will Decoy Therapeutics (DCOY) cover in the Corporate Connect presentation on February 10?
How can investors access the Decoy Therapeutics (DCOY) webcast on February 10, 2026?
Does Decoy Therapeutics (DCOY) plan to discuss clinical data during the Webull webinar on February 10, 2026?
